ST. LOUIS, Mo., June 20, 2024 /PRNewswire/ -- Express Scripts, the pharmacy benefits services business of Evernorth, a subsidiary of The Cigna Group (NYSE: CI), today released research spotlighting that members with employer-provided coverage paid less at the pharmacy counter for prescription drugs in 2023 compared to the previous year. On average, members with employer-sponsored drug coverage paid $15.10 out-of-pocket for a 30-day prescription in 2023, a decrease of about 1% compared to 2022. While drug manufacturers raised prices for 60% of branded drugs in 2023, data confirm that Express Scripts lowered out of pocket costs for these members as a result of its negotiations with pharmaceutical manufacturers and innovative solutions, even as consumer prices for goods and services increased in the United States from 2022 to 2023.
"Express Scripts continues to bring down medication costs for patients," said Adam Kautzner, Pharm.D., president of Evernorth Care Management and Express Scripts. "Despite rising costs of prescription drugs and inflation, our commercial members' average cost share has increased by no more than 1.1% year over year since 2020."
On average, members with employer-sponsored drug coverage paid $15.10 out of pocket for a 30-day prescription in 2023. For the entirety of 2023, four in five Express Scripts members – 81% – spent less than $250 out of pocket for their medicines, or about $20 per month. Nearly two-thirds of members spent even less, even as the median annual list price for a new drug reached $300,000 last year, according to a Reuters analysis, up from $222,000 a year earlier.
Additionally, Express Scripts' innovative programs keep costs down for the millions of commercial customers it serves, including by:
Kautzner said, "Across disease areas, Express Scripts holds drug manufacturers accountable for their prices and uses generic and biosimilar competition to help ensure patients who need these medications can afford them at the pharmacy counter."
About Evernorth Health Services
Evernorth Health Services creates pharmacy, care and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE: CI), or third-party partners. Learn more at evernorth.com.
Media Contact
Madeline Ziomek
(202) 615-1473
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$330.07 |
Daily Change: | 6.68 2.07 |
Daily Volume: | 1,294,524 |
Market Cap: | US$91.810B |
October 31, 2024 September 12, 2024 September 12, 2024 August 01, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB